Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis Mar 29, 2022
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update Mar 24, 2022
Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy Mar 16, 2022
Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis Mar 8, 2022
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations Feb 8, 2022
Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day Jan 31, 2022
Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January Jan 5, 2022